



The HealthAgents Project

IST-2004-27214

Mariola Mier
Co-ordinator
mariola@microart.es

Title

**Agent-based Distributed Decision Support
System for Brain Tumour Diagnosis and
Prognosis (IST-2004-27214)**

Acronym

HealthAgents

Provenance

- 3-year project funded by the EC under contract IST–2004–27214
- Sixth Framework Programme (FP6) Information Society Technologies
- Priority addressed: IST-2004-2.4.11 - Integrated biomedical information for better health
- Instrument: Specific Targeted Research Project (STREP)
- Information Society Technologies (IST) priority
- €4.1M total (€3.7M direct funding)
- 9 Partners



www.cordis.lu/ist/



Participants

- MicroArt, SL (Spain)
- Universitat de València (Spain)
- Universitat Autònoma de Barcelona (Spain)
- ITACA (Spain)
- Pharma Quality Europe (Italy)
- Katholieke Universiteit Leuven (Belgium)
- University of Birmingham (UK)
- University of Edinburgh (UK)
- University of Southampton (UK)



Objectives

SCIENTIFIC	TECHNOLOGICAL
Brain Tumour Classification	Large d-DWH
New Pattern Recognition Methods	Multi-Agent System
New Candidate DB Checking	New Ontology
“Self-learning” Classifiers	Auto-conversion of Tumour Data
“Trusted” Framework	Tumour Exchange Protocol
Dissemination	Classifiers & d-DWH Coupling
	Data Mart Comparison & Analysis
	Improved Classifiers
	Enhanced Security

Specific Objectives

- To improve the **healthcare** of patients with brain tumours
- To improve our **understanding** of brain tumours
- To make these improvements widely readily **accessible**


Why brain tumours?

- Clinical importance
 - Important cause of **morbidity** and **mortality** in adults and children
 - Few **improvements** in outcome
 - **New approaches** to management needed via greater **understanding**
- Amenable to techniques
 - Brain is amenable to **MR** studies
 - **Tissue available**, surgery mainstay of treatment

Challenges

Objective	Problem	Our solution
<p>Improve the (MRS-based) non-invasive classification (diagnosis/prognosis/progression and therapy follow-up) of brain tumours by using a distributed network of local databases or Data Marts (DM).</p>	<p>There are many brain tumour types and grades. Use of metabonomics or survival data may further increase this (sub)type number. Developing robust classifiers may require 10-15 examples of each tumour (sub)type.</p>	<p>Assuming about 6,000 MRI/MRS centers and 100 cases stored per center this provides a potential harvest field of 600,000 cases for classifier development. HealthAgents wants to set the bases, strategies and protocols for this harvest to start and to demonstrate it feasible.</p>
<p>Classification – histopathology is often a poor predictor of response Non-invasive diagnosis - surgery often associated with morbidity, Tumour assessment - size of tumour on MRI is a crude measure of amount of active tumour, heterogeneity, margins, biological variability Drug targets - New biological targets needed for drug development</p>	<p>Accessibility</p> <ul style="list-style-type: none"> Standardisation of acquisition Data formats Data processing and interpretation <p>Future proofing</p> <ul style="list-style-type: none"> Needs to be automatically updated <p>Local needs</p> <ul style="list-style-type: none"> Tailor to the population seen in the hospital Tailor the work carried out 	<p>Distributed databases and DSS</p> <ul style="list-style-type: none"> Clinician friendly presentation of data and guided interpretation Building of tailored local databases Continued updating <p>Ontologies</p> <ul style="list-style-type: none"> Improve classification by inclusion of more information Build dynamic systems – improved classification as more data is collected

Our Solution



Scheme of the HealthAgents network: Distributed Decision Support System (d-DSS) and Evidence-based Search Service (ebSS)